Director, Vidant Outpatient and Regional Oncology
East Carolina Univ
Physician Executive with expertise in management of GU malignancy and oncology operations.
@DrVickersUAB Congratulations Dr Vickers!! So well deserved and an amazing opportunity to lead one of the most prestigious cancer centers in the world :)
Tesla Plaid 2021: 1st rear tire worn out at 9k and 2nd rear at 12k miles. Neither Tesla/Michelin assume responsibility, be aware of additional costs of $2000 every 12k mi. Definitely expect better product from Michelin and product selection from Tesla @Tesla@elonmusk
@CGI_Atlanta I have my parents here in USA on tourist visa. Their passport is expiring on Sept 10, 2020 and US stay in valid until Aug 15, 2020. Applied for passport renewal but needs proof of residence. Can someone help. Thanks
Post-exposure Prophylaxis for #COVID19 RCT open NOW! 1500 patients, Hydroxychloroquine vs placebo x 7d prophylaxis for Healthcare workers & household contact—Enroll online! meds shipped. PI: @boulware_dr https://t.co/UUkZ1bCcwL
@rochgerionc @SPilleron@JGeriOnc Thanks for including me in reviewer list. Let me know how I can contribute meaningfully to the journal and medical community.
@rochgerionc @JGeriOnc Supriya: agree with your tweet and let me know if I can contribute to the journal in the capacity of a reviewer or member of editorial board. Thanks, Vijay.
Hannah Rush does great job presenting QOL abiraterone vs docetaxel in HSPC in #stampede. Clear evidence that abiraterone better #gu20 @MRCCTU @mattsydes
Phase I/II STUDY OF MK-648, small molecule HIF-2 inhibitor in #mRCC by @DrChoueiri of @DanaFarber w/ @ERPlimackMD et al @ASCO#GU20
MK-648 is safe and active in #ccRCC in all IMDC categories
In heavily treated pts
ORR=24%
DCR=80%
mPFS=11 mo
@TrevorHunt_ECU@ERPlimackMD Trevor, nice to hear from you and proud of your ECU roots. We should connect soon, keep me posted if you plan a trip to Brody!
Interesting data on SABR for renal masses presented by Dr Siva from Peter MacCallum #GU20 @ASCO. Enjoyed critique of SABR for mRCC in combination with CPI by @ThomasPowles (Barts Cancer Institute)
This is a great practical algorithm on figuring out Axitinib vs PD(L)1 toxicities when used in #mRCC. Axitinib has a short half life so should see quick resolution if due to axitinib. Thanks @ERPlimackMD. #GU20@ASCO#oncoalert
Enfortumab + Pembrolizumab in First line Phase 2 trial of advanced urothelial carcinoma: 73% ORR, PFS:12 months, OS: not reached. This combo is going to replace traditional chemotherapy in Rx of mUC soon. Presented by Jonathan Rosenberg @SocietyofMSKCC#GU20@ASCO
@ERPlimackMD@SGreenbergGC Thanks so much for your feedback and kind words! Please stop by the poster this eve to chat if you're around. Credit to @mikemorrison for leading the charge on this design. This has been my most valuable poster experience to date, so will definitely use this format going forward!